Lumasiran

  • TRADE NAME: Oxlumo (Alnylam Pharma Inc)
  • INDICATIONS: Treatment of primary hyperoxaluria type 1. To lower urinary oxalate levels in pediatric and adult patients. 
  • CLASS: Small interfering RNA (siRNA)
  • HALF-LIFE: approximately 5 hours

FDA APPROVAL DATE: 11/23/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known


No available data in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Our database has 2 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

GASTROINTESTINAL/HEPATIC.
LOCAL.


Page last updated 07/05/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top